PCI Biotech $PCIB bullish breaching 100EMA coming into Q4* Norwegian Drug Delivery Platform Biotech operating within the Oslo Cancer Cluster
* Notoriously volatile norwegian small cap with large amount of stock held by enthusiastic retail investor crowd.
* Ongoing research collaboration with AstraZeneca recently concluded, longs betting on partnership deal incoming.
* Stock typically rallies ahead of quarterly reports and experiences sell the news events.
* Norwegian biotech flying at All Time High valuations after recent Vaccibody partnership with Genentech.
